At least as far as this one goes it looks like Sandoz saw no advantages. My guess would be this one is Epo or Neulasta. I think this is a shrewd decision. mnta/sandoz should stick to areas where they may be the only filer or sole approval.
Item 8.01 Other Events
As previously disclosed, in June 2007, Momenta Pharmaceuticals, Inc. (the “Company”) and Sandoz AG (“Sandoz”) signed a Collaboration and License Agreement (the “2006 Collaboration”) to exclusively collaborate on the development and commercialization of four product candidates. Under the terms of the 2006 Collaboration, the Company and Sandoz agreed to (i) jointly develop, manufacture and commercialize M356, a generic version of Copaxone (glatiramer acetate), worldwide; (ii) expand the geographic markets related to M-Enoxaparin to include the European Union; and (iii) exclusively collaborate on the development and commercialization of two biosimilar products, referred to as M178 and M249.
On December 22, the Company and Sandoz agreed to terminate their collaborative program with regard to M249, primarily due to the commercial prospects for M249, including taking into consideration the number of marketed products that would be competing with M249 at the expected time of launch. Of the $188.0 million in milestone payments that the Company was eligible to receive under the 2006 Collaboration (if all milestones were achieved for the four product candidates), the milestone payments related to M249 totaled $10.0 million. The Company is continuing to collaborate with Sandoz on M356, M-Enoxaparin and M178.
2
Market Data 
Markets 
AI
